All Updates

All Updates

icon
Filter
Funding
Ability Biologics raises USD 18 million in seed funding to develop novel immunomodulators
AI Drug Discovery
Jun 18, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Yesterday
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Yesterday
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Yesterday
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Yesterday
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Yesterday
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Yesterday
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
AI Drug Discovery

AI Drug Discovery

Jun 18, 2024

Ability Biologics raises USD 18 million in seed funding to develop novel immunomodulators

Funding

  • AI-powered antibody therapeutics discovery company Ability Biologics has raised USD 18 million in a seed funding round led by Amplitude Ventures, with participation from Fonds de solidarité FTQ, Investissement Québec, Charles River Laboratories, Theodorus, and Alexandria Venture Investments.

  • The funds will be used to develop Ability's AI-enabled AbiLeap discovery platform, which generates logic-gated, fully human antibodies targeting specific tissues based on certain conditions, such as pH and temperature variations, for enhanced therapeutic selectivity and potency.

  • Canada-based Ability Biologics is focused on developing highly specific and selective antibody therapeutics to address unmet medical needs in cancer and autoimmune diseases. The company leverages its proprietary AbiLeap discovery platform, which uses AI and a database of antigen-antibody interactions.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.